Law360, New York (September 20, 2011, 1:38 PM ET) -- Valeant Pharmaceuticals International Inc. said Tuesday that the Federal Trade Commission had made two separate requests for additional information related to its $770 million plans to purchase a pair of companies that make skin care drugs.
The exact nature of the FTC's antitrust concerns was not immediately clear, but the company said in a statement that it still expected both deals to close before the end of the year.
The requests delay, at least temporarily, the Ontario-based company's July pickups of two dermatology units that would...
FTC Investigates Valeant's Dermatology Buys
To view the full article, take a free trial now.
